GAITHERSBURG, Md., June 7 /PRNewswire-FirstCall/ -- A study of more than 33,000 women published in the June issue of the Journal of the National Cancer Institute found that testing for high-risk types of the human papillomavirus (HPV) is a significantly more sensitive tool for cervical cancer screening than either conventional or liquid-based cytology (Pap testing), announced Digene Corp. (Nasdaq: DIGE - News). The study, which used Digene’s Hybrid Capture 2 High-Risk HPV DNA Test® (also called The Digene® HPV Test), was funded in part by the European Union and the Italian Ministry of Health.
